How to Avoid Myositis
The most critical strategy to prevent myositis is identifying and discontinuing causative medications, particularly statins and immune checkpoint inhibitors (ICPis), before muscle inflammation develops. 1
Primary Prevention Strategies
Medication Management
The most actionable prevention strategy involves careful medication review:
- Hold statins immediately if any early signs of muscle symptoms develop (myalgia, weakness, or elevated CK) 1
- Screen for drug-induced myopathy risk before starting medications known to cause myositis, including statins, checkpoint inhibitors, and other immunosuppressive agents 2
- For patients requiring ICPi therapy, recognize that anti-PD-1/PD-L1 agents carry higher myositis risk than anti-CTLA-4 agents 1
Early Detection Through Monitoring
Vigilant monitoring is essential for preventing progression to severe myositis:
- Monitor creatine kinase (CK) levels in any patient on high-risk medications who develops muscle symptoms 1
- Distinguish true weakness (inability to lift arms, stand from chair) from myalgia alone—weakness indicates myositis, pain alone typically does not 1
- Check troponin levels if myositis is suspected, as myocarditis carries high mortality and requires urgent intervention 1
Risk Stratification for ICPi Patients
For patients receiving immunotherapy, prevention focuses on early recognition:
- Assess for pre-existing paraneoplastic polymyositis or dermatomyositis before starting ICPi, as these can reactivate 1
- Screen for concomitant myasthenia gravis (anti-acetylcholine receptor antibodies), which combined with myositis carries an ominous prognosis 1
- Perform baseline EMG and MRI in high-risk patients to establish pre-treatment status 1
Secondary Prevention (Preventing Progression)
Grade 1 (Mild Weakness)
If early myositis develops:
- Continue to hold statins 1
- Consider prednisone 0.5 mg/kg/day if CK is elevated with documented weakness 1
- Provide analgesia with acetaminophen or NSAIDs for associated myalgia 1
Critical Warning Signs Requiring Immediate Action
Permanent discontinuation of ICPi is mandatory if:
- Bulbar symptoms develop (dysphagia, dysarthria, dysphonia) 3
- Dyspnea occurs (respiratory muscle involvement) 3
- Any evidence of myocarditis emerges 1
- Rhabdomyolysis develops 1
Special Populations
Malignancy-Associated Myositis
- Screen for underlying malignancy in adults with new-onset dermatomyositis (30% association) 4
- This should not delay myositis treatment, but cancer screening must occur concurrently 4
Overlap Syndromes
Monitor for inflammatory markers (ESR, CRP) and autoantibodies, as overlap with other rheumatologic conditions requires different management 3
Common Pitfalls to Avoid
Do not confuse polymyalgia rheumatica-like syndrome with true myositis—PMR has pain without weakness and normal CK levels 1
Do not restart ICPi until CK normalizes and clinical manifestations resolve completely in patients who developed Grade 2+ myositis 1
Do not delay referral to rheumatology/neurology for Grade 2+ symptoms—early specialist involvement improves outcomes 1, 3
Do not use plasmapheresis immediately after IVIG—it will remove the immunoglobulin 1
The evidence consistently demonstrates that myositis prevention hinges on medication vigilance and early detection rather than primary prophylaxis, as there are no proven preventive therapies for idiopathic inflammatory myopathies themselves.